Abstract: Disclosed herein are method and compounds useful in the analysis, diagnosis, and treatment of high grade serous ovarian carcinoma (HGSOC). Also disclosed are methods, compounds, and compositions useful in regulating Chromobox 2 (CBX2) expression and therapies for stem-ness, anoikis escape, HGSOC dissemination, and HGSCO chemoresistance. Applicants have identified CBX2 expression as being significantly elevated in HGSOC cells and tissues compared to benign counterparts. Also disclosed is elevated CBX2 expression in HGSOC cell lines, as well as elevated CBX2 expression in cells that are forced to grown in suspension. Reducing CBX2 results in inhibition of anchorage-independent proliferation and potentiation of anoikis-dependent apoptosis, as well as re-sensitization of HGSOC cells to platinum-based chemotherapy.

Abstract: Observations regarding the role of MUC1 in promoting the nuclear accumulation of EGFR led us to propose the development of peptides to block nuclear accumulation of EGFR as a means to block breast cancer progression. One exemplary peptide, the ENLS1 peptide, promotes cell death in breast cancer cell lines. Studies in the MMTV-pyMT mouse model of breast cancer demonstrate significant anti-tumor activity.

Abstract: Observations regarding the role of MUC1 in promoting the nuclear accumulation of EGFR led us to propose the development of peptides to block nuclear accumulation of EGFR as a means to block breast cancer progression. One exemplary peptide, the ENLS1 peptide, promotes cell death in breast cancer cell lines. Studies in the MMTV-pyMT mouse model of breast cancer demonstrate significant anti-tumor activity.